Targeting cholesterol metabolism in aggressive breast cancer
Lysosomal metabolism as a targetable driver of pancreatic cancer
This study is looking at how certain aggressive breast cancer cells change and how we might be able to use that information to find new ways to treat Triple Negative Breast Cancer, especially for patients who have trouble with current treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10889082 on NIH RePORTER |
What this research studies
This research focuses on understanding the metabolic dependencies of Triple Negative Breast Cancer (TNBC) cells, which are known for their aggressive nature and limited treatment options. By investigating how these cancer cells undergo changes during a process called epithelial-to-mesenchymal transition (EMT), the research aims to identify new therapeutic targets. The study utilizes microRNA-200c to revert TNBC cells to a more epithelial-like state, which may reveal important alterations in cholesterol metabolism that could be exploited for treatment. Through this approach, the research seeks to uncover novel strategies to combat resistance to standard therapies in TNBC patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Triple Negative Breast Cancer who may benefit from novel therapeutic strategies targeting cholesterol metabolism.
Not a fit: Patients with other subtypes of breast cancer or those who do not have access to the specific treatments being investigated may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with Triple Negative Breast Cancer, potentially improving their prognosis and survival rates.
How similar studies have performed: Other research has shown promise in targeting metabolic pathways in cancer treatment, suggesting that this approach may yield significant advancements.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: O'neill, Kathleen — University of California, San Francisco
- Study coordinator: O'neill, Kathleen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.